CellSource Co., Ltd. (JP:4880) has released an update.
CellSource Co., Ltd. has announced significant downward revisions to its full-year financial forecasts for fiscal year 2024, citing a decrease in contracts for its stem cell processing services, particularly from medical institutions with self-funded treatments. The company’s revised forecast anticipates decreases in net sales, operating profit, ordinary profit, and profit earnings per share, with overall changes ranging from -18.5% to -58.1%. Despite a partial increase in non-operating income from a government subsidy, the reduction in contracts and operating profit has led to these adjustments.
For further insights into JP:4880 stock, check out TipRanks’ Stock Analysis page.